Ocular hypotony has been in the spotlight following recent BBC News coverage highlighting how new clinical research is delivering meaningful benefits for patients affected by this sight threatening condition. The feature draws attention to a newly published study from the Moorfields Eye Hospital team exploring an innovative, minimally invasive management strategy using an ophthalmic viscosurgical device (OVD).
The study, titled “Novel therapeutic strategies to restore vision in ocular hypotony (STRETCH): results from a prospective pilot series,” was published in the British Journal of Ophthalmology in January 2026. It reports encouraging early clinical outcomes using Bausch + Lomb’s EYEFILL® H.D. as a therapeutic option in selected patients with ocular hypotony. Ocular hypotony, characterised by abnormally low intraocular pressure, can lead to significant visual impairment and structural complications if not effectively managed.
The pilot series evaluates the intravitreal use of the highly dispersive OVD to help restore intraocular pressure and provide sustained internal ocular support. EYEFILL® H.D. is a high dispersive OVD, supplied in a 2.5 ml syringe, and contains 2% hydroxypropylmethylcellulose (HPMC) in a physiological saline solution. Bausch + Lomb is proud that EYEFILL® H.D. has played a role in this important clinical investigation and in supporting patient care.
The company extends sincere congratulations to Mr Harry Petruskin and the entire Moorfields team for their contribution to advancing the management of ocular hypotony. To learn more about EYEFILL® H.D. and the wider EYEFILL® range of ophthalmic viscosurgical devices, please contact your local Bausch + Lomb representative for further information and support.
FURTHER INFORMATION:
Bausch + Lomb
W: https://www.linkedin.com/company/bausch-surgical-international/
